Literature DB >> 10783384

Abnormal sodium stimulation of carnitine transport in primary carnitine deficiency.

Y Wang1, T A Meadows, N Longo.   

Abstract

Primary carnitine deficiency is an autosomal recessive disorder of fatty acid oxidation characterized by hypoketotic hypoglycemia and skeletal and cardiac myopathy. It is caused by mutations in the sodium-dependent carnitine cotransporter OCTN2. The majority of natural mutations identified in this and other Na(+)/solute symporters introduce premature termination codons or impair insertion of the mutant transporter on the plasma membrane. Here we report that a missense mutation (E452K) identified in one patient with primary carnitine deficiency did not affect membrane targeting, as assessed with confocal microscopy of transporters tagged with the green fluorescent protein, but reduced carnitine transport by impairing sodium stimulation of carnitine transport. The natural mutation increased the concentration of sodium required to half-maximally stimulate carnitine transport (K(Na)) from the physiological value of 11.6 to 187 mm. Substitution of Glu(452) with glutamine (E452Q), aspartate (E452D), or alanine (E452A) caused intermediate increases in the K(Na). Carnitine transport decreased exponentially with increased K(Na). The E452K mutation is the first natural mutation in a mammalian cotransporter affecting sodium-coupled solute transfer and identifies a novel domain of the OCTN2 cotransporter involved in transmembrane sodium/solute transfer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10783384     DOI: 10.1074/jbc.M000194200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Functional and molecular studies in primary carnitine deficiency.

Authors:  Marta Frigeni; Bijina Balakrishnan; Xue Yin; Fernanda R O Calderon; Rong Mao; Marzia Pasquali; Nicola Longo
Journal:  Hum Mutat       Date:  2017-09-14       Impact factor: 4.878

2.  Glycosylation of the OCTN2 carnitine transporter: study of natural mutations identified in patients with primary carnitine deficiency.

Authors:  Cristina Amat di San Filippo; Orly Ardon; Nicola Longo
Journal:  Biochim Biophys Acta       Date:  2010-11-29

3.  Genotype-phenotype correlation in primary carnitine deficiency.

Authors:  Emily C Rose; Cristina Amat di San Filippo; Uzochi C Ndukwe Erlingsson; Orly Ardon; Marzia Pasquali; Nicola Longo
Journal:  Hum Mutat       Date:  2011-10-11       Impact factor: 4.878

4.  Contributions of phosphorylation to regulation of OCTN2 uptake of carnitine are minimal in BeWo cells.

Authors:  Erik Rytting; Kenneth L Audus
Journal:  Biochem Pharmacol       Date:  2007-09-19       Impact factor: 5.858

5.  Wide tolerance to amino acids substitutions in the OCTN1 ergothioneine transporter.

Authors:  Marta Frigeni; Francesco Iacobazzi; Xue Yin; Nicola Longo
Journal:  Biochim Biophys Acta       Date:  2016-03-16

6.  L-carnitine transport in kidney of normotensive, Wistar-Kyoto rats: effect of chronic L-carnitine administration.

Authors:  Lucía Gómez-Amores; Alfonso Mate; Carmen M Vázquez
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

7.  Cardiomyopathy and carnitine deficiency.

Authors:  Cristina Amat di San Filippo; Matthew R G Taylor; Luisa Mestroni; Lorenzo D Botto; Nicola Longo
Journal:  Mol Genet Metab       Date:  2008-03-11       Impact factor: 4.797

Review 8.  Carnitine transport and fatty acid oxidation.

Authors:  Nicola Longo; Marta Frigeni; Marzia Pasquali
Journal:  Biochim Biophys Acta       Date:  2016-01-29

9.  Identification and characterization of a carnitine transporter in Acinetobacter baumannii.

Authors:  Jennifer Breisch; Izabela Waclawska; Beate Averhoff
Journal:  Microbiologyopen       Date:  2018-10-14       Impact factor: 3.139

Review 10.  Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications.

Authors:  Hermann Koepsell; Katrin Lips; Christopher Volk
Journal:  Pharm Res       Date:  2007-05-01       Impact factor: 4.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.